Companies / SYK
NYSEStryker Corporation (SYK) in our theses
Stryker Corporation appears in one of our theses. Below is why it entered the basket and how it has done since publication.
The GLP-1 Paradox: Anti-Obesity Drugs Are Not Killing Orthopedics, They Are Unlocking Joint Replacement Backlogs
Patients losing weight on GLP-1s drop below BMI thresholds that previously disqualified them from surgery, unleashing pent-up demand for knee and hip replacements.
Why this company: Market leader in orthopedic reconstruction powered by the Mako surgical robotics ecosystem; captures expanding procedure share across hospital and ambulatory surgery centers.
Where these numbers come from
The reference price is recorded on the thesis publication date and never changed afterwards. The current price is refreshed several times a day. Returns are in the listing currency and exclude dividends, so for dividend payers the real total return was somewhat higher.
This is not a recommendation to buy or sell. A company enters a basket as a beneficiary of the mechanism described in the thesis, and the full argument is on each thesis page.
See all of our theses
Each with a publication date, a causal map and a score assigned before the market ruled.
Open in Invesaro →